387 related articles for article (PubMed ID: 25638562)
1. Nivolumab success in untreated metastatic melanoma.
Wilkinson E
Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638562
[No Abstract] [Full Text] [Related]
2. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
3. Dramatic Survival Benefit with Nivolumab in Melanoma.
Cancer Discov; 2016 Jun; 6(6):OF7. PubMed ID: 27091855
[TBL] [Abstract][Full Text] [Related]
4. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
6. [Immune checkpoint antibodies increase survival in patients with metastatic melanoma].
Fløe LE; Svane IM; Bastholt L; Schmidt H
Ugeskr Laeger; 2016 Aug; 178(33):. PubMed ID: 27550784
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab (Yervoy) and inoperable or metastatic melanoma. More evaluation needed, in both first- and second-line use.
Prescrire Int; 2015 Apr; 24(159):96. PubMed ID: 25941700
[No Abstract] [Full Text] [Related]
8. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
Di Giacomo AM; Margolin K
Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364
[TBL] [Abstract][Full Text] [Related]
9. [PD-1 Antibodies. A new therapeutic option for metastatic malignant melanoma].
Hafner C
Hautarzt; 2012 Sep; 63(9):724-5. PubMed ID: 22956035
[No Abstract] [Full Text] [Related]
10. Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?
Kim KB
Cancer; 2013 Feb; 119(3):477-80. PubMed ID: 22915026
[No Abstract] [Full Text] [Related]
11. Nivolumab in previously untreated melanoma without BRAF mutation.
Robert C; Long GV; Brady B; Dutriaux C; Maio M; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Arance A; Schmidt H; Schadendorf D; Gogas H; Lundgren-Eriksson L; Horak C; Sharkey B; Waxman IM; Atkinson V; Ascierto PA
N Engl J Med; 2015 Jan; 372(4):320-30. PubMed ID: 25399552
[TBL] [Abstract][Full Text] [Related]
12. [Nivolumab for metastatic melanoma-basic knowledge and clinical data].
Yamazaki N; Maeda Y
Gan To Kagaku Ryoho; 2015 Apr; 42(4):434-8. PubMed ID: 26020984
[No Abstract] [Full Text] [Related]
13. Melanoma: understanding relevant molecular pathways as well as available and emerging therapies.
McKibbin T
Am J Manag Care; 2015 Sep; 21(10 Suppl):S224-33. PubMed ID: 26619296
[TBL] [Abstract][Full Text] [Related]
14. New drug targets in metastatic melanoma.
Homet B; Ribas A
J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
[TBL] [Abstract][Full Text] [Related]
15. Programmed death protein 1 inhibitors making inroads in multiple cancers.
Brower V
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
[No Abstract] [Full Text] [Related]
16. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab for Metastatic Melanoma.
Gupta AK; Daigle D
Skin Therapy Lett; 2016 Mar; 21(2):6-9. PubMed ID: 27223114
[TBL] [Abstract][Full Text] [Related]
18. PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis.
Lin Z; Chen X; Li Z; Luo Y; Fang Z; Xu B; Han M
PLoS One; 2016; 11(8):e0160485. PubMed ID: 27483468
[TBL] [Abstract][Full Text] [Related]
19. PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma.
Schneiderbauer R; Schneiderbauer M; Wick W; Enk AH; Haenssle HA; Hassel JC
Acta Derm Venereol; 2017 Mar; 97(3):395-396. PubMed ID: 27868138
[No Abstract] [Full Text] [Related]
20. Immune Checkpoint Therapy in Melanoma.
Callahan MK
Cancer J; 2016; 22(2):73-80. PubMed ID: 27111901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]